Liberate Bio has obtained both exclusive and non-exclusive licences for patents related to chimeric antigen receptor (CAR) designs tailored for myeloid cells, such as monocytes and macrophages. The ...
Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells, announces that it has secured exclusive and non-exclusive licenses to key ...
A conference devoted entirely to bioplastics, biocomposites and cars? To bioplastics Magazine and the Germany-based nova-Institute, it sounded like a concept that couldn’t miss. Now, after the dust ...
BrainChild Bio’s initial CAR T-cell therapy program will focus on advancing ongoing clinical trials evaluating safety and efficacy in pediatric brain tumors. SEATTLE--(BUSINESS WIRE)--Seattle Children ...
SHANGHAI and NANJING, China and PLEASANTON, Calif., March 24, 2026 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company focused on the discovery, development, ...
Adds proprietary CAR sequence IP to Liberate’s selective in vivo delivery platform, strengthening the foundation of its emerging CAR-M therapeutic class Liberate Bio, Inc., a biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results